Australia markets closed
  • ALL ORDS

    7,624.30
    +23.80 (+0.31%)
     
  • ASX 200

    7,368.90
    +9.90 (+0.13%)
     
  • AUD/USD

    0.7487
    -0.0064 (-0.85%)
     
  • OIL

    71.50
    +0.46 (+0.65%)
     
  • GOLD

    1,763.90
    -10.90 (-0.61%)
     
  • BTC-AUD

    48,049.73
    +47.31 (+0.10%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • AUD/EUR

    0.6308
    -0.0028 (-0.44%)
     
  • AUD/NZD

    1.0787
    +0.0009 (+0.09%)
     
  • NZX 50

    12,551.93
    +10.73 (+0.09%)
     
  • NASDAQ

    14,049.58
    -114.22 (-0.81%)
     
  • FTSE

    7,017.47
    -135.96 (-1.90%)
     
  • Dow Jones

    33,290.08
    -533.37 (-1.58%)
     
  • DAX

    15,448.04
    -279.63 (-1.78%)
     
  • Hang Seng

    28,801.27
    +242.68 (+0.85%)
     
  • NIKKEI 225

    28,964.08
    -54.25 (-0.19%)
     

Azure Health Technology Limited (VTL.NSX) Initiation Report

·1-min read
Azure Health Technology Limited (NSX:VTL)
Azure Health Technology Limited (NSX:VTL)

Azure Health Technology Limited (VTL.NSX) Initiation Report

Sydney, Australia, June 8, 2021 - (ABN Newswire) - Azure Health Technology Limited (NSX:VTL) trading as VGI Health Technology is pleased to announce that Pitt Street Research has issued an Initiation Report.

VTL's CEO and Managing Director, Dr Glenn Tong, said that the founder and senior analyst of Pitt Street Research, Stuart Roberts, was one of the most experienced research analysts in the Australian biotechnology industry.

"We are very pleased that Stuart Roberts has invested time into analysing the VTL story," Dr Tong said.

"Stuart has done a great job in articulating the value proposition which VTL presents and how similar companies have successfully commercialised pharmaceutical products derived from natural sources. He also explains in very clear and simple terms how VTL's drug development and nutraceuticals business will add considerable value to the Company."

To view the report, please visit:
https://www.abnnewswire.net/lnk/8YY77965



About Azure Health Technology Limited:


Azure Health Technology Limited (NSX:AZT) develops and commercializes evidence-based nutraceuticals and pharmaceuticals based on two proprietary and patented delivery platforms for improving the bioavailability and efficacy of tocotrienols (a natural product which is one part of vitamin E).

Contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

Andrew Crook, Investor and Media Relations
Ph:+61 (0) 419 788 431

Source:
Azure Health Technology Limited

Copyright (C) 2021 ABN Newswire. All rights reserved.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting